Ann: Investor Briefings & Webinar Notice, page-75

First 75 Last

Share
Profile

Follow
Jakjazz

2,971 Posts.

1090

17/07/24

10:35

Post #: 74789243
Share

Originally posted by Jockthegreat: ↑

Good to have a clearer picture on trial timeline and what to expect along the path. I am not sure we will get much SP appreciation from here though as broadly speaking it will be now viewed as a 12-18 month waiting period with not much in the middle (accounting for model testing for other conditions). Outside of a buyout before phase 2 results (imo possible but unlikely), investors may not want to tie up capital now when they can do it in 12 months time, closer to readout.

Not that it matters in the long run.

I think most who believe are largely locked and loaded and now the 'final' wait begins.

Let's hope all of the OLE participants remain alive well beyond expectations and MPL continues to help them experience QOL above and beyond SOC.

Expand

Beg to differ JTG but continuous reporting of results from the OLE will provide a catalyst for further price appreciation. Not only that but results of MPL testing for other neurodegenerative diseases will surely provide strong SP support. We also the MPL liquid formulation, IND, patient enrollment and first dosing of >200 patients to provide a SP kicker.

Together with worldwide investor exposure provided by acceptance to Healey PAA will be on the radar of the big players so I do see significant SP upside in the next 12 months

Can BP allow such developments without commencing M&A activity, I doubt it

PAA Price at posting: 22.5¢ Sentiment: Buy Disclosure: Held
33 Upvote

6 Great analysis

Reply

Top Stories

TLG

Talga Group wins key permit for flagship graphite mine in Sweden

SNX

Sierra Nevada raises $2M for silver exploration at Blackhawk

MTH

Mithril's drilling in Mexico picks up silver at 997g/t, gold at 28g/t

M4M

Macro, Norden set up transport solutions initiative for West Pilbara

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

NVU

Nanoveu surges 10% after benchmark testing for new AI chip begins

Week 42 Wrap: HotCopper's top picks; new ASX 200 record; world yawns at war

What's causing the cost-of-living crisis, and how to navigate it

IRX

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint